Biokosmos actively supports innovation in Nuclear Medicine by
collaborating with leading companies and institutions in the field.
Conducting in-house research, we contribute to the development of
cutting-edge radiopharmaceuticals, including theragnostic solutions that
combine molecular imaging diagnosis and targeted radiation treatment.
These partnerships help advance personalized treatments of cancer,
ensuring more precise diagnosis and effective therapies tailored to each
patient’s needs.